Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs MDLive

Maves
Graded #88

Higher grade

vs+13
MDLive
Graded #357

Lower grade

The verdict

Maves takes it — 71.8/100 to 58.8/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +39
84
45
Dose & formulationMaves +12
65
53
Clinical oversightMDLive +9
76
85
Labs & monitoringMDLive +2
52
54
FulfillmentMaves +25
87
62
Contract termsEven
55
55
Maves · left barMDLive · right bar

The numbers

MetricMavesMDLive
WeighScore71.8/10058.8/100
GradeCC
Scorecard rank#88#357
Semaglutide$99/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
MDLive

Graded #357 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s including Wegovy and Zepbound
  • Covered through insurance and employer benefits for 50M-plus people
  • Board-certified physicians averaging about 15 years of experience
  • Part of Evernorth/Cigna, a large established healthcare organization
  • Offers full primary care, not just a single weight-loss funnel

Where it loses points

  • GLP-1s only at clinician discretion in a Primary Care routine visit
  • Anti-obesity meds not available in FL, LA, MS or NJ
  • Distributed mainly via insurers and employers; cost varies by plan
  • No transparent published monthly cash price for GLP-1 care

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard